Buyback of Class B shares in Essity during week 47, 2024
The share purchase is part of the
The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation.
Class B shares in Essity were repurchased as follows:
Date | Aggregated daily volume (no. of shares): | Weighted average price per day (SEK): | Total daily transaction value (SEK): |
54,000 | 296.7058 | 16,022,113 | |
54,000 | 295.4498 | 15,954,289 | |
54,000 | 297.1945 | 16,048,503 | |
54,000 | 297.9977 | 16,091,876 | |
54,000 | 300.7783 | 16,242,028 | |
Total accumulated during week 47, 2024 | 270,000 | 297.6252 | 80,358,809 |
Total accumulated during the buyback program | 6,156,000 | 300.6345 | 1,850,705,968 |
All purchases were conducted on Nasdaq Stockholm by Danske Bank on behalf of Essity. Following the above purchases, Essity's holding of treasury shares amounted on
The full details concerning the completed transactions are appended to this press release.
For further information, please contact:
Sandra Åberg, Vice President Investor Relations, +46 70 564 96 89, [email protected]
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/essity/r/buyback-of-class-b-shares-in-essity-during-week-47--2024,c4071075
The following files are available for download:
Buyback of Class B shares in Essity during week 47, 2024 | |
https://mb.cision.com/Public/15798/4071075/bdf5ee4be51f2c73.pdf | Essity transactions week 47 |
View original content:https://www.prnewswire.com/news-releases/buyback-of-class-b-shares-in-essity-during-week-47-2024-302315377.html
SOURCE Essity
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Magnoli Technologies Adds Native Payroll Processing, Closing the Last Gap Between Schedule and Paycheck for Dry Cleaning Operators
- Lingokids Just Launched Spanish and Portuguese: Why Families Will Love It
- Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Dividend, Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share